The Food and Drug Administration (FDA) recently issued a safety warning
for people taking the drug Multaq (dronedarone), a drug approved two years
ago for the treatment of irregular heart rhythms.
The FDA warning cited data from a recently cancelled study that was being
conducted by Sanofi-Aventis, the maker of Multaq. In the study, twice
as many deaths occurred in a group of people taking Multaq compared to
a group that did not take the drug.
The FDA approved Multaq in 2009 for the treatment of arrhythmia lasting
less than six months, a condition called short-term or non-permanent atrial
fibrillation. Since then 241,000 Americans have been issued prescriptions
for the drug. The study was being conducted to determine whether Multaq
could be used to treat permanent or long-term atrial fibrillation.
The warning advises all patients taking Multaq to consult their physician
to determine whether they should continue taking the drug. It also tells
doctors to not prescribe Multaq for the treatment of long-term arrhythmia.
If you or someone you know has suffered a serious adverse reaction to Multaq, consider
consulting a personal injury attorney who specializes in dangerous drugs and can advise you of your legal rights.